Richard J O'Callaghan

US Patent:

7906498, Mar 15, 2011

Filed:

Apr 6, 2005

Appl. No.:

11/099854

Inventors:

Mary E. Marquart - Jackson MS, US
Richard J. O'Callaghan - Ridgeland MS, US

Assignee:

Board of Supervisors of Louisiana State University And Agricultural and Mechanical College - Baton Rouge LA

International Classification:

A61K 31/56

US Classification:

514178, 514912

Abstract:

Topical application of cholesterol has been found to be effective in preventing, treating or ameliorating the damage to the cornea caused by. Topical administration of cholesterol caused a significant decrease in the inflammation of the eye. In addition, cholesterol was surprisingly found to be a bactericide to outside the cornea. The effect of cholesterol can be enhanced by further administering a steroid or an antibiotic to the cornea.

US Patent:

63159961, Nov 13, 2001

Filed:

Apr 9, 1999

Appl. No.:

9/289684

Inventors:

Richard J. O'Callaghan - Slidell LA

Assignee:

Board of Supervisors of Louisiana State University and Agricultural and
Mechanical College - Baton Rouge LA

International Classification:

A61K 3848
C12N 948
C12N 950

US Classification:

424 9463

Abstract:

A method has been discovered for using lysostaphin as an effective antibiotic for topical treatment of Staphylococcus corneal infections (keratitis). Lysostaphin applied topically to the cornea by eye drops killed bacteria within the cornea; lysostaphin reduced the number of bacteria from approximately 10,000,000 viable bacteria colony forming units ("CFU") in the untreated eye to essentially no viable bacteria in the treated eyes. Treatment by lysostaphin was more potent than any of the smaller antibiotics that have been previously tested (e. g. , tetracyclines, erythromycins, cephalosporins, vancomycin, aminoglycosides, or fluoroquinolones). Moreover, topical application of lysostaphin was effective against the highly antibiotic-resistant Staphylococcus strains.